Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tilsotolimod plus Nivolumab and Ipilimumab in Solid Tumors (SCCHN Cohort)
2018-003690-10Phase 2Terminated
- Sponsor
- Aceragen, Inc.
- Start
- May 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 2, single-arm trial of tilsotolimod, nivolumab and ipilimumab in head and neck squamous cell carcinoma (HNSCC), sponsored by Aceragen, Inc. Primary endpoint: Safety and tolerability (Part 1). Started May 2019; status: terminated.
02
Drugs
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on 2018-003690-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-003690-10.